Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model

被引:19
作者
Fingleton, Barbara [1 ]
Carter, Kathy J. [1 ]
Matrisian, Lynn M. [1 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA
关键词
D O I
10.1158/0008-5472.CAN-06-4473
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fas ligand (FasL/CD95L), a member of the tumor necrosis factor family, interacts with a specific receptor Fas, ultimately leading to cell death. Tumor expression of FasL has been proposed to aid in immune evasion through a "Fas counter-attack" mechanism but has also been described as a proinflammatory factor. Here, we tested the role of FasL in a mouse model of spontaneous tumor development. We used the Min mouse in which multiple benign polyps develop in the intestine due to a mutation in the Apc tumor suppressor gene. Mutant mice deficient in functional FasL, termed gld/gld, were crossed to Min mice to generate tumor-prone animals lacking functional FasL. Comparison of FasL-deficient versus proficient Min mice revealed a significant increase in polyp number in the gld/gld mice. We next assessed immune cell infiltration into adenomas. There was no difference in the number of either lymphocytes or macrophages; however, the number of tumor-infiltrating neutrophils was 3-fold lower in the gld/gld specimens compared with controls. Neutrophil migration in vitro was stimulated by wild-type but not mutant FasL. In a nontumor-bearing colitis model in vivo, neutrophil recruitment to the intestine was also reduced in gld/gld mice. Although the Fas counterattack hypothesis suggests that the absence of Fast, would result in increased immune-mediated tumor elimination, the opposite is true in the Min model with lack of functional Fast, associated with reduced neutrophil influx and increased tumor development. Thus, the proinflammatory rather than counterattack role of tumor FasL is more relevant.
引用
收藏
页码:4800 / 4806
页数:7
相关论文
共 52 条
[1]   Extracellular matrix interacts with soluble CD95L: Retention and enhancement of cytotoxicity [J].
Aoki, K ;
Kurooka, M ;
Chen, JJ ;
Petryniak, J ;
Nabel, EG ;
Nabel, GJ .
NATURE IMMUNOLOGY, 2001, 2 (04) :333-337
[2]   Gene transfer of Fas ligand induces tumor regression in vivo [J].
Arai, H ;
Gordon, D ;
Nabel, EG ;
Nabel, GJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (25) :13862-13867
[3]  
Beck P, 2002, GASTROENTEROLOGY, V122, pA269
[4]   Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence [J].
Belluco, C ;
Esposito, G ;
Bertorelle, R ;
Alaggio, R ;
Giacomelli, L ;
Bianchi, LC ;
Nitti, D ;
Lise, M .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2002, 28 (02) :120-125
[5]   Regulation of the proinflammatory effects of Fas ligand (CD95L) [J].
Chen, JJ ;
Sun, YN ;
Nabel, GJ .
SCIENCE, 1998, 282 (5394) :1714-1717
[6]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[7]   The immunobiology of cancer immunosurveillance and immunoediting [J].
Dunn, GP ;
Old, LJ ;
Schreiber, RD .
IMMUNITY, 2004, 21 (02) :137-148
[8]   Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis [J].
Fingleton, B ;
Vargo-Gogola, T ;
Crawford, HC ;
Matrisian, LM .
NEOPLASIA, 2001, 3 (06) :459-468
[9]   A rat monoclonal antibody that recognizes pro- and active MMP-7 indicates polarized expression in vivo [J].
Fingleton, Barbara ;
Powell, William C. ;
Crawford, Howard C. ;
Couchman, John R. ;
Matrisian, Lynn M. .
HYBRIDOMA, 2007, 26 (01) :22-27
[10]   Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover [J].
French, LE ;
Hahne, M ;
Viard, I ;
Radlgruber, G ;
Zanone, R ;
Becker, K ;
Muller, C ;
Tschopp, J .
JOURNAL OF CELL BIOLOGY, 1996, 133 (02) :335-343